Piciclib 125MG Capsule (21’s) is a targeted oral medication primarily used in the treatment of certain types of breast cancer, particularly hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The active ingredient in this formulation is Palbociclib, which is a cyclin-dependent kinase (CDK) 4/6 inhibitor. This drug works by interfering with the cancer cell cycle, thereby inhibiting the proliferation of cancer cells. Each capsule contains 125 mg of Palbociclib, and the packaging typically includes 21 capsules, which is designed to facilitate a standard treatment regimen. Piciclib is often prescribed in combination with aromatase inhibitors or other hormonal therapies to enhance its efficacy. The drug is well-regarded for its ability to extend progression-free survival in patients, making it a vital option in the oncology therapeutic arsenal.